Novartis Announced Results from Year Two of Phase III Trial of Beovu in Diabetic Macular Edema Confirm Year One Findings With Overall Favorable Benefit-risk Pprofile

by | Dec 9, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.